Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;24(9):e960-e967.
doi: 10.1634/theoncologist.2018-0474. Epub 2019 Apr 11.

"How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer

Claribel Simmons  1 , Donald C McMillan  2 , Sharon Tuck  3 , Cat Graham  3 , Alistair McKeown  4 , Mike Bennett  5 , Claire O'Neill  6 , Andrew Wilcock  7 , Caroline Usborne  8 , Kenneth C Fearon  1 , Marie Fallon  1 , Barry J Laird  9   10 ; IPAC Study Group
Collaborators, Affiliations

"How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer

Claribel Simmons et al. Oncologist. 2019 Sep.

Abstract

Background: The optimal prognostic factors in patients with advanced cancer are not known, as a comparison of these is lacking. The aim of the present study was to determine the optimal prognostic factors by comparing validated factors.

Materials and methods: A multicenter, prospective observational cohort study recruited patients over 18 years with advanced cancer. The following were assessed: clinician-predicted survival (CPS), Eastern Cooperative Oncology Group performance status (ECOG-PS), patient reported outcome measures (anorexia, cognitive impairment, dyspnea, global health), metastatic disease, weight loss, modified Glasgow Prognostic Score (mGPS) based on C-reactive protein and albumin, lactate dehydrogenase (LDH), and white (WCC), neutrophil (NC), and lymphocyte cell counts. Survival at 1 and 3 months was assessed using area under the receiver operating curve and logistic regression analysis.

Results: Data were available on 478 patients, and the median survival was 4.27 (1.86-7.03) months. On univariate analysis, the following factors predicted death at 1 and 3 months: CPS, ECOG-PS, mGPS, WCC, NC (all p < .001), dyspnea, global health (both p ≤ .001), cognitive impairment, anorexia, LDH (all p < .01), and weight loss (p < .05). On multivariate analysis ECOG-PS, mGPS, and NC were independent predictors of survival at 1 and 3 months (all p < .01).

Conclusion: The simple combination of ECOG-PS and mGPS is an important novel prognostic framework which can alert clinicians to patients with good performance status who are at increased risk of having a higher symptom burden and dying at 3 months. From the recent literature it is likely that this framework will also be useful in referral for early palliative care with 6-24 months survival.

Implications for practice: This large cohort study examined all validated prognostic factors in a head-to-head comparison and demonstrated the superior prognostic value of the Eastern Cooperative Oncology Group performance status (ECOG-PS)/modified Glasgow Prognostic Score (mGPS) combination over other prognostic factors. This combination is simple, accurate, and also relates to quality of life. It may be useful in identifying patients who may benefit from early referral to palliative care. It is proposed ECOG-PS/mGPS as the new prognostic domain in patients with advanced cancer.

Keywords: Cancer; Inflammation; Palliative; Prognosis; Survival.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

References

    1. Blanke CD, Fromme EK. Chemotherapy near the end of life: First–and third and fourth (line)–do no harm. JAMA Oncol 2015;1:785–786. - PubMed
    1. Earle CC, Neville BA, Landrum MB et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315–321. - PubMed
    1. Steinhauser KE, Christakis NA, Clipp EC et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000;284:2476–2482. - PubMed
    1. Fairclough DL, Cella DF. Eastern Cooperative Oncology Group (ECOG). J Natl Cancer Inst Monogr 1996:73–75. - PubMed
    1. Maltoni M, Caraceni A, Brunelli C et al. Prognostic factors in advanced cancer patients: Evidence‐based clinical recommendations—A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240–6248. - PubMed

Publication types

MeSH terms

LinkOut - more resources